Vischer with Kuros Biosciences on royalty purchase agreement with Xoma

Kuros Biosciences, a bone graft technologies company, has entered into a royalty purchase agreement with Xoma Corporation, under which Xoma has purchased a proportion of the potential future pre-commercial milestone payments and all the potential royalties due under the existing license agreement between Kuros and Checkmate Pharmaceuticals related to one of Kuros’s assets outside of the bone graft field.

Vischer has been acting as legal counsel to Kuros Biosciences in Swiss law matters along the U.S. lead counsel. The Vischer team is led by Matthias Staehelin (partner, corporate/m&a, pictured top left) with Sebastian Flückiger (senior associate, corporate/m&a, pictured top right)

Kuros will receive an initial payment of $7 million from Xoma.  In addition, Kuros retains the potential to receive up to $24 million in pre-commercial milestones from Checkmate and is eligible to receive up to $142.5 million in sales milestones from Xoma.